Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease

American Journal of Managed Care

Volumn 13, Issue 2, 2007, Pages 73-79

  Tiwari, Anjali ^a   Tseng, Chin Lin ^a   Kern, Elizabeth F O ^b   Maney, Miriam ^a   Miller, Donald R ^c,d   Pogach, Leonard ^a,e  

^a UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e DVA New Jersey Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CORRELATION COEFFICIENT; DATA BASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG USE; ELECTRONIC MEDICAL RECORD; EVALUATION; FEASIBILITY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; UNITED STATES; AGE DISTRIBUTION; CHRONIC KIDNEY FAILURE; CLASSIFICATION; DRUG ANTAGONISM; DRUG UTILIZATION; HOSPITALIZATION; MEDICAL RECORD; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLIC HOSPITAL;

ADULT; AGE DISTRIBUTION; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITALS, VETERANS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTICENTER STUDIES; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 33847174264     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. US Renal Data System. USRDS 2000 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 2000.
2. Coresti J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
3. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121-1129.
4. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DM. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-663.
5. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003;16:101-105.
6. Jafar TH, Start PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-252.
7. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
8. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
10. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131-140.
11. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
12. Agency for Healthcare Research and Quality. National Healthcare Quality Report, 2003, Available at: http://www.ahrq.gov/qual/nhqr03/nhqr03.htm. Accessed May 1, 2004.
13. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avom J. Underuse of ACEI inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46:1080-1087.
14. Kizer KW. The "new VA": a national laboratory for health care quality management. Am J Med Qual. 1999;14:3-20.
15. Hynes DM, Perrin RA, Rappaport S, Stevens JM, Demakis JG. Informatics resources to support health care quality improvement in the Veterans Health Administration. J Am Med Inform Assoc. 2004;11:344-350.
16. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Veterans Health Administration based on computerized patient data. Diabetes Care. 2004;27(suppl 2):B10-B21.
17. National Center for Chronic Disease Prevention and Health Promotion. Diabetes fact sheet. Available at: http://www.cdc.gov/ diabetes/pubs/factsheet.htm. Accessed July 26, 2006.
18. Kem EO, Maney M, Miller DR, et al. Failure of diagnosis codes to identify patients with co-morbid chronic kidney disease in diabetes. Health Serv Res. 2006;41:564-580.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Meet. 1999;130:461-470.
20. National Committee for Quality Assurance. HEDIS 2001. Vol. 1. Washington, DC: National Committee for Quality Assurance; 2000.
21. National Committee for Quality Assurance. NCQA report cards. Available at: http://hprc.ncqa.org/menu.asp. Accessed July 26, 2006.
22. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA. 2003;289:305-312.
23. Kvanli AH, Guynes SC, Pavur RJ, eds. Introduction to Business Statistics. 4th ed. St. Paul, Minn: West Publishing Company; 1996.
24. Keating NL, Landrum MB, Landon BE, Ayanian JZ, Borbas C, Guadagnoli E. Measuring the quality of diabetes care using administrative data: is there bias? Health Serv Res. 2003;38:1529-1545.
25. Hofer TP, Hayward RA, Greenfield S, Wagner EH, Kaplan SH, Manning WG. The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease. JAMA. 1999;281:2098-2105.
26. Ward MM, Yankey JW, Vaughn TE, et al. Physician process and patient outcome measures for diabetes care: relationships to organizational characteristics. Med Care. 2004;42:840-850.
27. Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis. 2005;46:406-414.
28. Akbari A, Swedko PJ, Clark HD, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med. 2004;164:1788-1792.
29. Hebert LA. Optimizing ACEI inhibitor therapy for chronic kidney disease. N Engl J Med. 2006;354:189-191.
30. Minutolo R, De Nicola L, Zamboli P, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46:18-25.
31. Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144:172-180.
32. Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with "poor quality" actually getting good care? Med Care. 2003;41:1173-1182.
33. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
34. Berwick DM, James B, Coyle MJ. Connections between quality measurement and improvement. Med Care. 2003;41(1 suppl):I30-I38.